Asymmetric data acquisition system for an endoscopic PET-US detector

According to current prognosis studies of pancreatic cancer, survival rate nowadays is still as low as 6% mainly due to late detections. Taking into account the location of the disease within the body and making use of the level of miniaturization in radiation detectors that can be achieved at the present time, EndoTOFPET-US collaboration aims at the development of a multimodal imaging technique for endoscopic pancreas exams that combines the benefits of high resolution metabolic information from time-of- flight (TOF) positron emission tomography (PET) with anatomical information from ultrasound (US). A system with such capabilities calls for an application-specific high-performance data acquisition system (DAQ) able to control and readout data from different detectors. The system is composed of two novel detectors: a PET head extension for a commercial US endoscope placed internally close to the region-of-interest (ROI) and a PET plate placed over the patient's abdomen in coincidence with the PET head. These two detectors will send asymmetric data streams that need to be handled by the DAQ system. The approach chosen to cope with these needs goes through the implementation of a DAQ capable of performing multi-level triggering and which is distributed across two different on-detector electronics and the off-detector electronics placed inside the reconstruction workstation. This manuscript provides an overview on the design of this innovative DAQ system and, based on results obtained by means of final prototypes of the two detectors and DAQ, we conclude that a distributed multi-level triggering DAQ system is suitable for endoscopic PET detectors and it shows potential for its application in different scenarios with asymmetric sources of data

Anisotropy of the electric field gradient in two-dimensional alpha-MoO_(3) investigated by (57)^Mn((57)^Fe) emission mossbauer spectroscopy

Van der Waals alpha-MoO_(3) samples offer awide range of attractive catalytic, electronic, and optical properties. We present herein an emission Mossbauer spectroscopy (eMS) study of the electric-field gradient (EFG) anisotropy in crystalline free-standing alpha-MoO_(3) samples. Although alpha-MoO3 is a twodimensional (2D) material, scanning electron microscopy shows that the crystals are 0.5-5-mu m thick. The combination of X-ray diffraction and micro-Raman spectroscopy, performed after sample preparation, provided evidence of the phase purity and crystal quality of the samples. The eMS measurements were conducted following the implantation of (57)^Mn (t(1/ 2) = 1.5 min), which decays to the (57)^Fe, 14.4 keV Mossbauer state. The eMS spectra of the samples are dominated by a paramagnetic doublet (D1) with an angular dependence, pointing to the Fe^(2+) probe ions being in a crystalline environment. It is attributed to an asymmetric EFG at the eMS probe site originating from strong in-plane covalent bonds and weak out-of-plane van derWaals interactions in the 2D material. Moreover, a second broad component, D2, can be assigned to Fe^(3+) defects that are dynamically generated during the online measurements. The results are compared to ab initio simulations and are discussed in terms of the in-plane and out-of-plane interactions in the syste

Efeitos e aplicabilidade da terapia espelho na neurorreabilitação - revisão de literatura / Effects and applicability of mirror therapy in neurorehabilitation - literature review

Introdução: A Terapia Espelho (TE) foi originalmente desenvolvida na década de 90, pelo neurocientista indiano Ramachandran. A técnica utiliza um espelho posicionado no plano médio sagital, entre o membro afetado e o membro saudável, fornecendo feedback visual do membro saudável e gerando a sensação de dois membros móveis, como se o membro afetado estivesse realizando movimentos saudáveis no hemicampo negligenciado. Isso resulta na excitabilidade corticoespinhal e das áreas somatossensoriais, contribuindo para a recuperação motora. Objetivo: Identificar a aplicabilidade e os efeitos da Terapia Espelho como recurso da reabilitação neurológica.   Materiais e métodos: Trata-se de uma revisão de literatura, onde as bases de dados utilizadas foram Pedro, SciELO, PubMed e Lilacs, no período de Setembro de 2017 a Outubro de 2018. Utilizou-se como estratégia de pesquisa, nas bases de dados, a combinação dos descritores de acordo com o idioma. Além disso, foi realizada a busca manual na lista de referências dos artigos apresentados. Os estudos foram submetidos a uma avaliação da qualidade metodológica, utilizando-se a escala PeDro. Resultados: Foram encontrados 62 artigos, porém apenas 9 foram analisados. Eram compostos por amostras de indivíduos com diagnóstico de dor fantasma por amputação, Paralisia Cerebral (PC), lesão traumática cerebral ou Acidente Vascular Cerebral (AVC) em suas fases aguda, subaguda e crônica. Os instrumentos de avaliação variaram entre os estudos, assim como o modo de execução, a frequência e a duração do tratamento. Conclusão: A TE é benéfica para a recuperação motora de membros superiores e inferiores, função sensório-motora e para a diminuição da dor. Porém, a literatura voltada para o modo de execução da TE é muito escassa e existem muitas controvérsias em relação ao protocolo utilizado, tornando-se necessária a realização de novos estudos com maior número amostral, de modo que possam obter resultados mais significativos e amplos

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study

AIM: The SARS-CoV-2 pandemic has provided a unique opportunity to explore the impact of surgical delays on cancer resectability. This study aimed to compare resectability for colorectal cancer patients undergoing delayed versus non-delayed surgery. METHODS: This was an international prospective cohort study of consecutive colorectal cancer patients with a decision for curative surgery (January-April 2020). Surgical delay was defined as an operation taking place more than 4 weeks after treatment decision, in a patient who did not receive neoadjuvant therapy. A subgroup analysis explored the effects of delay in elective patients only. The impact of longer delays was explored in a sensitivity analysis. The primary outcome was complete resection, defined as curative resection with an R0 margin. RESULTS: Overall, 5453 patients from 304 hospitals in 47 countries were included, of whom 6.6% (358/5453) did not receive their planned operation. Of the 4304 operated patients without neoadjuvant therapy, 40.5% (1744/4304) were delayed beyond 4 weeks. Delayed patients were more likely to be older, men, more comorbid, have higher body mass index and have rectal cancer and early stage disease. Delayed patients had higher unadjusted rates of complete resection (93.7% vs. 91.9%, P = 0.032) and lower rates of emergency surgery (4.5% vs. 22.5%, P < 0.001). After adjustment, delay was not associated with a lower rate of complete resection (OR 1.18, 95% CI 0.90-1.55, P = 0.224), which was consistent in elective patients only (OR 0.94, 95% CI 0.69-1.27, P = 0.672). Longer delays were not associated with poorer outcomes. CONCLUSION: One in 15 colorectal cancer patients did not receive their planned operation during the first wave of COVID-19. Surgical delay did not appear to compromise resectability, raising the hypothesis that any reduction in long-term survival attributable to delays is likely to be due to micro-metastatic disease

Dementia in Latin America : paving the way towards a regional action plan

Regional challenges faced by Latin American and Caribbean countries (LACs) to fight dementia, such as heterogeneity, diversity, political instabilities, and socioeconomic disparities, can be addressed more effectively grounded in a collaborative setting based on the open exchange of knowledge. In this work, the Latin American and Caribbean Consortium on Dementia (LAC-CD) proposes an agenda for integration to deliver a Knowledge to Action Framework (KtAF). First, we summarize evidence-based strategies (epidemiology, genetics, biomarkers, clinical trials, nonpharmacological interventions, networking and translational research) and align them to current global strategies to translate regional knowledge into actions with transformative power. Then, by characterizing genetic isolates, admixture in populations, environmental factors, and barriers to effective interventions and mapping these to the above challenges, we provide the basic mosaics of knowledge that will pave the way towards a KtAF. We describe strategies supporting the knowledge creation stage that underpins the translational impact of KtAF

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure &lt;= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt